RedHill Biopharma (RDHL) Accounts Payables (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Accounts Payables data on file, last reported at $731000.0 in Q4 2025.

• On a quarterly basis, Accounts Payables fell 37.41% year-over-year to $731000.0 in Q4 2025; TTM through Dec 2025 was $731000.0, a 37.41% decrease from a year earlier, with the FY2025 full-year figure at $731000.0, down 37.41% from the prior year.
• Accounts Payables for Q4 2025 stood at $731000.0, down from $835000.0 in the prior quarter.
• Over the last five years, Accounts Payables for RDHL reached as high as $15.2 million in Q3 2021 and fell as low as $731000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $5.4 million across 5 years, with a median of $4.4 million in 2023.
• Across the five-year window, Accounts Payables soared 150.68% in 2021 and sank 68.62% in 2022, its largest moves.
• Year by year, Accounts Payables stood at $11.7 million in 2021, then plunged by 63.73% to $4.2 million in 2022, then fell by 22.51% to $3.3 million in 2023, then slumped by 64.37% to $1.2 million in 2024, then sank by 37.41% to $731000.0 in 2025.
• Per Business Quant data, the three most recent Accounts Payables figures were $731000.0 in Q4 2025, $835000.0 in Q2 2025, and $1.2 million in Q4 2024.